Accessibility Menu
Csl logo

Csl(OTC) CMXHF

Market Cap$46.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+1,169%
5 Year-51%
1 Year-40%
1 Month+13%
$98.03
+0.77%
+0.75Today
Csl last closing stock price
MetricPriceDate
Last closeUSD 98.032026-08-14
Csl stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+7%USD 91.622026-08-07
1 month+13.49%USD 86.382026-07-14
3 month+39.05%USD 70.502026-05-15
Year to date-14%USD 113.982025-12-31
1 year-40.31%USD 164.232025-08-14
3 year-37.8%USD 157.602023-08-15
5 year-50.75%USD 199.042021-08-13
Since inception+1,169.21%USD 7.722003-06-25

Csl Financials at a Glance

Market Cap

$46.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$30.65B

Net Income (TTM)

$4.19B

EPS (TTM)

$2.87

P/E Ratio

33.99

Dividend

$2.92

Beta (Volatility)

0.32 (Low)

Price

$98.03

Volume

932

Open

$97.92

Previous Close

$98.03

Daily Range

$97.92 - $98.03

52-Week Range

$63.84 - $179.00

Estimated Earnings Date

Aug 18, 2026

CMXHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Csl

CSL Limited is a global biopharmaceutical enterprise focused on the discovery, development, production, marketing, and distribution of a diverse range of medicinal products. With operations in key markets such as Australia, the United States, and China, CSL Limited is organized into two main divisions: CSL Behring and Seqirus.

Products and Services
  • CSL Behring specializes in plasma-derived therapies for serious conditions
  • Seqirus develops innovative influenza vaccines and non-plasma biotherapeutics
  • Research and development in both plasma and non-plasma-based treatments
Growth Outlook
  • Revenue of $8.44 billion in the latest quarter shows strong demand
  • Operating income margin improved to 31.3% in Q2 2025
  • Continued investment in R&D supports long-term growth potential
Financial Highlights
  • Net income of $408 million reported for Q2 2025
  • Trailing twelve months (TTM) dividend yield of 3.46% indicates strong returns
  • Operating cash flow of $1.33 billion in the latest quarter reflects solid financial health
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

29,000

CEO

Paul McKenzie, PhD

Website

www.csl.com.au

Headquarters

Melbourne, VIC 3000, AU

CMXHF Financials

Key Financial Metrics (TTM)

Gross Margin

48.64%

Operating Margin

25.72%

Net Income Margin

9.17%

Return on Equity

7.56%

Return on Capital

9.60%

Return on Assets

3.80%

Earnings Yield

2.94%

Dividend Yield

2.98%

Payout Ratio

1.03%

Stock Overview

Market Cap

$46.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

478.91M

Volume

932

Avg. Volume

4.00K

Financials (TTM)

Gross Profit

$15.29B

Operating Income

$8.00B

EBITDA

$9.95B

Operating Cash Flow

$6.72B

Capital Expenditure

-$1.34B

Free Cash Flow

$5.38B

Cash & ST Invst.

$1.15B

Total Debt

$12.58B

Csl Performance Analysis

Csl annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 10,493,100,000N/A
20232023-06-30USD 13,174,000,00025.5%
20242024-06-30USD 14,690,000,00011.5%
20252025-06-30USD 15,430,000,0005.0%
Csl sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-19.3%
Q22024-12-3121.7%
Q42025-06-30-11.7%
Q22025-12-3116.3%
Csl annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD 4.80N/A
20232023-06-30USD 4.64-3.3%
20242024-06-30USD 5.4517.4%
20252025-06-30USD 6.1713.4%
Csl sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-62.6%
Q22024-12-31169.9%
Q42025-06-30-48.7%
Q22025-12-31-60.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$8.44B

+0.9%

Gross Profit

$4.28B

-0.3%

Gross Margin

50.68%

N/A

Market Cap

$46.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.62M

N/A

Employees

29,000

N/A

Net Income

$408.33M

-79.4%

EBITDA

$3.14B

-1.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.15B

+12.9%

Total Debt

$12.58B

+4.1%

Accounts Receivable

$4.14B

+16.4%

Inventory

$6.57B

+18.4%

Long Term Debt

$11.86B

+4.0%

Short Term Debt

$717.43M

-53.9%

Return on Assets

3.80%

N/A

Return on Invested Capital

12.12%

N/A

Free Cash Flow

$1.02B

+167.5%

Operating Cash Flow

$1.33B

+18.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
UCBJYUCB S.A.
$122.60-2.83%
UCBJFUCB S.A.
$254.59-3.23%
SEMHFSiemens Healthineers AG
$46.91+2.49%
HOCPYHOYA Corporation
$167.15-0.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About CMXHF

What is the current price of Csl?

Csl is trading at $98.03 per share.

What is the 52-week range for Csl?

Over the past 52 weeks, Csl has traded between $63.84 and $179.00.

How much debt does Csl have?

As of the most recent reporting period, Csl reported total debt of $11.50B.

How much cash does Csl have on hand?

Csl reported $2.16B in cash and cash equivalents in its most recent financial results.

What is Csl’s dividend yield?

Csl currently has a dividend yield of 2.98%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services